Abstract
Phosphodiesterase 10A (PDE10A) inhibitors are expected to be novel drugs for schizophrenia through activation of both direct and indirect pathway medium spiny neurons. However, excess activation of the direct pathway by a dopamine D1 receptor agonist SKF82958 canceled antipsychotic-like effects of a dopamine D2 receptor antagonist haloperidol in methamphetamine (METH)-induced hyperactivity in rats. Thus, balanced activation of these pathways may be critical for PDE10A inhibitors. Current antipsychotics and the novel PDE10A inhibitor TAK-063, but not the selective PDE10A inhibitor MP-10, produced dose-dependent antipsychotic-like effects in METH-induced hyperactivity and prepulse inhibition in rodents. TAK-063 and MP-10 activated the indirect pathway to a similar extent; however, MP-10 caused greater activation of the direct pathway than did TAK-063. Interestingly, the off-rate of TAK-063 from PDE10A in rat brain sections was faster than that of MP-10, and a slower off-rate PDE10A inhibitor with TAK-063-like chemical structure showed an MP-10-like pharmacological profile. In general, faster off-rate enzyme inhibitors are more sensitive than slower off-rate inhibitors to binding inhibition by enzyme substrates. As expected, TAK-063 was more sensitive than MP-10 to binding inhibition by cyclic nucleotides. Moreover, an immunohistochemistry study suggested that cyclic adenosine monophosphate levels in the direct pathway were higher than those in the indirect pathway. These data can explain why TAK-063 showed partial activation of the direct pathway compared with MP-10. The findings presented here suggest that TAK-063’s antipsychotic-like efficacy may be attributable to its unique pharmacological properties, resulting in balanced activation of the direct and indirect striatal pathways.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Burbaud P (2012). Dystonia Pathophysiology: A Critical Review. In: Raymond Rosales (ed.). Dystonia - The Many Facets. InTech: Rijeka, Croatia, pp 199-220.
Charych EI, Jiang LX, Lo F, Sullivan K, Brandon NJ (2010). Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia. J Neurosci 30: 9027–9037.
DeLong MR (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13: 281–285.
DeMartinis N, Banerjee A, Kumar V, Boyer S, Schmidt C, Arroyo S (2012). Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of Schizophrenia. Schizophrenia Res 136: S262.
Fukushima S, Shen H, Hata H, Ohara A, Ohmi K, Ikeda K et al (2007). Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl) 193: 55–62.
Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr. et al (1990). D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429–1432.
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156: 117–154.
Grace AA, Bunney BS (1985). Opposing effects of striatonigral feedback pathways on midbrain dopamine cell activity. Brain Res 333: 271–284.
Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R et al (2009). Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331: 574–590.
Haddad EB, Mak JC, Barnes PJ (1994). Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 45: 899–907.
Harada A, Suzuki K, Kamiguchi N, Miyamoto M, Tohyama K, Nakashima K et al (2015a). Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor. PLoS ONE 10: e0122197.
Harada A, Suzuki K, Miura S, Hasui T, Kamiguchi N, Ishii T et al (2015b). Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A. Nucl Med Biol 42: 146–154.
Jäger R, Russwurm C, Schwede F, Genieser HG, Koesling D, Russwurm M (2012). Activation of PDE10 and PDE11 phosphodiesterases. J Biol Chem 287: 1210–1219.
Janavs JL, Aminoff MJ (1998). Dystonia and chorea in acquired systemic disorders. J Neurol Neurosurg Psychiatry 65: 436–445.
Jones CA, Watson DJ, Fone KC (2011). Animal models of schizophrenia. Br J Pharmacol 164: 1162–1194.
Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 1081–1090.
Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S et al (1996). High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 153: 948–950.
Kunitomo J, Yoshikawa M, Fushimi M, Kawada A, Quinn JF, Oki H et al (2014). Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyri dazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. J Med Chem 57: 9627–9643.
Mailly P, Charpier S, Menetrey A, Deniau JM (2003). Three-dimensional organization of the recurrent axon collateral network of the substantia nigra pars reticulata neurons in the rat. J Neurosci 23: 5247–5257.
Megens AA, Hendrickx HM, Hens KA, Fonteyn I, Langlois X, Lenaerts I et al (2014). Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs. J Pharmacol Exp Ther 349: 138–154.
Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T et al (2008). Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28: 10460–10471.
Nishi A, Snyder GL, Greengard P (1997). Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17: 8147–8155.
Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C et al (1993). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227–235.
Obeso JA, Rodriguez-Oroz M, Marin C, Alonso F, Zamarbide I, Lanciego JL et al (2004). The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62: S17–S30.
Ouagazzal AM, Jenck F, Moreau JL (2001). Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology (Berl) 156: 273–283.
Pani L, Pira L, Marchese G (2007). Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry 22: 267–275.
Paylor R, Crawley JN (1997). Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl) 132: 169–180.
Podda MV, Riccardi E, D'Ascenzo M, Azzena GB, Grassi C (2010). Dopamine D1-like receptor activation depolarizes medium spiny neurons of the mouse nucleus accumbens by inhibiting inwardly rectifying K+ currents through a cAMP-dependent protein kinase A-independent mechanism. Neuroscience 167: 678–690.
Russwurm C, Koesling D, Russwurm M (2015). Phosphodiesterase 10A is tethered to a synaptic signaling complex in striatum. J Biol Chem 290: 11936–11947.
Sano H, Nagai Y, Miyakawa T, Shigemoto R, Yokoi M (2008). Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 105: 546–556.
Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF et al (2008). Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325: 681–690.
Shirley E (1977). A non-parametric equivalent of Williams’ test for contrasting increasing dose levels of a treatment. Biometrics 33: 386–389.
Simpson JN, McGinty JF (1995). Forskolin induces preproenkephalin and preprodynorphin mRNA in rat striatum as demonstrated by in situ hybridization histochemistry. Synapse 19: 151–159.
Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD et al (2013). The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 64: 215–223.
Stoof JC, Kebabian JW (1981). Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366–368.
Suzuki K, Harada A, Shiraishi E, Kimura H (2015). In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents. J Pharmacol Exp Ther 352: 471–479.
Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X et al (2009). Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem 52: 5188–5196.
Walters DE, Howard SG (1990). The D1 agonist SKF 38393 increases dopamine release in the developing rat striatum. Eur J Pharmacol 184: 257–264.
Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E et al (2012). Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol 12: 2.
Williams DA (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27: 103–117.
Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG et al (2006). Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139: 597–607.
Yoshikawa M, Kamisaki H, Kunitomo J, Oki H, Kokubo H, Suzuki A et al (2015). Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor. Bioorg Med Chem 23: 7138–7149.
Acknowledgements
We thank the following Takeda Pharmaceutical Company Limited employees: T Ishii for conducting in vitro PDE enzyme assays, M Harada for evaluating dopamine release by in vivo microdialysis, and T Taniguchi for synthesizing compounds.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Supplementary information
Rights and permissions
About this article
Cite this article
Suzuki, K., Harada, A., Suzuki, H. et al. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms. Neuropsychopharmacol 41, 2252–2262 (2016). https://doi.org/10.1038/npp.2016.20
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2016.20
This article is cited by
-
Phosphodiesterase inhibitors in psychiatric disorders
Psychopharmacology (2023)
-
Phosphodiesterase 10A Is a Critical Target for Neuroprotection in a Mouse Model of Ischemic Stroke
Molecular Neurobiology (2022)
-
The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome
Neurotherapeutics (2021)
-
Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type
Translational Stroke Research (2021)
-
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on l-DOPA-induced dyskinesia in parkinsonian rats
Pharmacological Reports (2020)
